The 81st Hospital of People's Liberation Army
Welcome,         Profile    Billing    Logout  
 21 Trials 
17 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Qin, Shukui
NCT03236649: The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects

Terminated
3
89
RoW
Icaritin, Sorafenib Tosylate Tablets
Beijing Shenogen Biomedical Co., Ltd, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Eastern Theater General Hospital,QinHuai District Medical Area, Peking University Cancer Hospital & Institute, Chinese PLA General Hospital, Beijing Hospital, General Hospital of Chinese Armed Police Forces, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Jinan Central Hospital, Linyi Cancer Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Nanfang Hospital of Southern Medical University, First People's Hospital of Foshan, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Tianjin Medical University Cancer Institute and Hospital, The Fourth Hospital of Hebei Medical University, Hunan Cancer Hospital, The First Hospital of Jilin University, 307 Hospital of PLA, Fudan University, Henan Cancer Hospital, Jilin Provincial Tumor Hospital, First Affiliated Hospital of Harbin Medical University, First Affiliated Hospital Bengbu Medical College, The First Affiliated Hospital of Soochow University, Tongji Hospital, Beijing YouAn Hospital
Hepatocellular Carcinoma (HCC)
02/22
02/22
CARES-310, NCT03764293 / 2019-000220-18: A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

Jan 2024 - Dec 2024: Submission for adjuvant HCC
Checkmark Data in combination with rivoceranib (apatinib) vs. sorafenib as a 1L unresectable HCC
Sep 2022 - Sep 2022: Data in combination with rivoceranib (apatinib) vs. sorafenib as a 1L unresectable HCC
Checkmark FDA granted for the treatment of HCC
Apr 2021 - Apr 2021: FDA granted for the treatment of HCC
More
Completed
3
543
Europe, US, RoW
SHR-1210, Camrelizumab, Apatinib, Rivoceranib, Sorafenib
Jiangsu HengRui Medicine Co., Ltd.
Locally Advanced or Metastatic and Unresectable HCC
02/22
06/23
NCT04914598: A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions

Not yet recruiting
3
290
RoW
ENDOSTAR，cisplatin, Placebo , cisplatin
Jiangsu Simcere Pharmaceutical Co., Ltd.
Malignant Pleural Effusion
06/22
10/23
NCT03236636: The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects

Recruiting
3
312
RoW
Icaritin, SNG-162, HUACHANSU PIAN, HUACHANSU PIAN（999）
Beijing Shenogen Biomedical Co., Ltd, Chinese Academy of Medical Sciences, NanJing PLA 81 Hospital, Peking University Cancer Hospital & Institute, Beijing Hospital, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Jinan Central Hospital, Linyi Tumour Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Nanfang Hospital of Southern Medical University, First People's Hospital of Foshan, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Hebei Medical University Fourth Hospital, The First Hospital of Jilin University, Haikou People's Hospital, Fudan University, West China Hospital, Chongqing Traditional Chinese Medicine Hospital, Chifeng Municipal Hospital, The Affiliated Hospital of Hangzhou Normal University, The First Affiliated Hospital of Zhengzhou University, Guilin Medical University, China, The Third Xiangya Hospital of Central South University, Yunnan Provincial Hospital of Traditional Chinese Medicine, The Sixth People's Hospital of Shenyang
Advanced HBV-Related Hepatocellular Carcinoma (HCC)
12/22
12/22
NCT03605706: A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment.

Recruiting
3
396
RoW
SHR-1210, FOLFOX4, Placebo
Jiangsu HengRui Medicine Co., Ltd.
Advanced Hepatocellular Carcinoma
02/23
12/23
KN035-BTC, NCT03478488: Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC

Active, not recruiting
3
480
RoW
KN035 plus Gemcitabine & oxaliplatin, Experimental, Gemcitabine & oxaliplatin, Active Comparator
3D Medicines (Sichuan) Co., Ltd.
Biliary Tract Neoplasms
01/25
01/25
JS001-027-III-HCC, NCT04523493 / 2020-004437-20: Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC

Active, not recruiting
3
530
Europe, RoW
Toripalimab combined with Lenvatinib, Placebo combined with Lenvatinib
Shanghai Junshi Bioscience Co., Ltd., Shanghai Junshi Biosciences Co., Ltd
Advanced Hepatocellular Carcinoma (HCC)
05/25
09/26
SHR-8068-301, NCT06618664: Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma

Recruiting
3
560
RoW
SHR-8068, Adebrelimab, Bevacizumab, Sintilimab
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Hepatocellular Carcinoma
03/26
12/30
NCT04183478: The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer

Recruiting
2/3
600
RoW
K-001, placebo, K-001 placebo
RenJi Hospital
Pancreatic Cancer
03/21
03/21
2023-012-00CH1, NCT06361888: A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Recruiting
2/3
482
RoW
Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine, Nab-paclitaxel Plus Gemcitabine, Surufatinib with Nab-paclitaxel, and Gemcitabine
Hutchmed
Metastatic Pancreatic Cancer
08/27
08/27
DUBHE-H-308, NCT05976568: A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Not yet recruiting
2/3
668
RoW
QL1706, Bevacizumab, Oxaliplatin injection, Capecitabine, Sintilimab
Qilu Pharmaceutical Co., Ltd.
Hepatocellular Carcinoma
09/27
09/27
NCT03941574: A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy

Recruiting
2
108
RoW
HLX10
Shanghai Henlius Biotech
MSI-H Solid Malignant Tumor
05/24
06/26
AST-3424-001, NCT06239155: A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors

Recruiting
1/2
51
RoW
AST-3424
Ascentawits Pharmaceuticals, Ltd
Advanced Solid Tumors, Hepatocellular Carcinoma
11/25
11/25
NCT05357196: PT-112 (Phosplatin's Platinum) Combine With Gemcitabine Injection for Advanced Solid Tumors

Recruiting
1/2
68
RoW
PT-112, Gemcitabine
SciClone Pharmaceuticals
Biliary Tract Cancer
08/22
04/23
SHR-1701-II-203, NCT04679038: A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors

Recruiting
1/2
222
RoW
SHR-1701, Famitinib
Jiangsu HengRui Medicine Co., Ltd.
Solid Tumor
12/22
10/23
BGB-900-104, NCT03941873: A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer

Hourglass Jan 2021 - Dec 2021 : Additional data from trial in combination with tislelizumab for HCC and gastric cancer
Completed
1/2
111
RoW
Sitravatinib, MGCD516, Tislelizumab, BGB-A317, Tevimbra
BeiGene
Carcinoma, Hepatocellular, Gastric/Gastroesophageal Junction Cancer
03/23
03/23
NCT04503902: Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma

Recruiting
1/2
46
RoW
Donafenib Tosilate Tablets, Donafenib, Toripalimab Injection, JS001
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Advanced Hepatocellular Carcinoma
12/23
12/23
kui, qin shu
No trials found

Download Options